Rhinothermy delivered by nasal high flow therapy in the treatment of the common cold: a randomised controlled trial.

ABSTRACT:

Background

The common cold is the most common infectious disease affecting humans and has a substantial economic impact on society. Human rhinoviruses, which cause almost two-thirds of colds, have demonstrated temperature-dependent replication which is optimal between 33°C and 35°C.

Methods

This randomised, single-blind, parallel-group trial completed at a single-centre in New Zealand, recruited 170 participants aged 18-75 years (mean age 27.5 years) who were within 48 hours of common cold symptom onset and had a symptom score (the Modified Jackson Score (MJS)) ≥7 and a negative point-of-care test for influenza. Participants were blinded to the intervention and randomised (1:1) to 5 days of either nasal high flow rhinothermy (rNHF) (100% humidified air delivered at 35 L/min

SUBMITTER: Bird G 

PROVIDER: S-EPMC8634207 | biostudies-literature | 2021 Nov

REPOSITORIES: biostudies-literature